Is McKesson Stock Worth Buying as Growth Meets a Premium Valuation?

McKesson Corporation MCK enters fiscal 2027 with double-digit earnings growth, faster expansion in specialty businesses and sizable capital returns. Those strengths support the long-term case, but the shares now trade above important historical and industry valuation benchmarks.

That leaves investors with a tighter decision. The operating story is improving, yet the current multiple leaves less room for execution misses, policy changes or a slowdown in earnings momentum.

McKesson's Growth Case Remains Strong

McKesson raised fiscal 2027 adjusted earnings guidance to $44.20-$45.00 per share, implying 13%-15% growth. Management also continues to target long-term adjusted earnings growth of 13%-16%, supported by organic growth, operating leverage and capital allocation.

The mix is moving toward higher-growth specialty platforms. First-quarter Oncology & Multispecialty revenues increased 33% and adjusted operating profit rose 41%, while Prescription Technology Solutions operating profit advanced 13%. The U.S. Oncology Network now includes about 3,400 providers and treats more than 2 million patients annually.

Cencora, Inc. COR provides a useful industry reference point. It reported 5.1% revenue growth in its fiscal 2026 third quarter and raised full-year adjusted earnings guidance, showing that pharmaceutical distribution and specialty exposure continue to support growth across the group.

MCK's Premium Valuation Limits the Margin for Error

McKesson trades at 18.4X forward 12-month earnings, above its five-year median of 15.7X and the Zacks sub-industry multiple of 17.6X. The current valuation remains below its five-year high of 22.8X, but it already prices in a meaningful portion of the earnings-growth story.

That premium raises the importance of consistent execution. Cardinal Health, Inc. CAH, another major pharmaceutical and specialty distributor, underscores the competitive scale of the sector. Investors paying above McKesson's historical median will likely want continued specialty growth and operating leverage to justify the higher multiple.

Image Source: Zacks Investment Research

McKesson's Capital Returns Support Per-Share Growth

McKesson repurchased $2.5 billion of stock in the first quarter, including $2.25 billion through an accelerated program. Full-year guidance anticipates about $5 billion of repurchases, reinforcing management's commitment to returning excess capital.

The board also raised the quarterly dividend 15% to 94 cents per share. McKesson expects diluted weighted-average shares of 115.5 million to 117.5 million for fiscal 2027, down from 124.1 million in fiscal 2026, which should continue to support per-share earnings growth.

MCK Still Faces Concentration and Policy Risks

Customer concentration remains a material risk. McKesson's 10 largest customers accounted for about 73% of fiscal 2026 consolidated revenues, while its largest customer represented roughly 24%. That exposure increases sensitivity to contract renewals, purchasing changes and service requirements.

Policy uncertainty adds another layer. Drug-pricing and reimbursement changes, 340B developments and manufacturer contracting behavior can affect revenue presentation, service fees and customer economics. Separation-related financing for Medical-Surgical Solutions also increases interest expense and adds execution complexity.

McKesson's Hold Signal Balances the Trade-Off

The bottom line is that McKesson's growth profile remains attractive, but the valuation offers less margin for error than it did at its historical median. The combination favors patience over chasing the shares after a strong rerating.

MCK currently carries a Zacks Rank #3 (Hold), along with a Value Score of A, Growth Score of A, Momentum Score of A and VGM Score of A. The Style Scores point to favorable characteristics across several investment approaches, but they are designed to complement the Zacks Rank. With a Hold rank, the stock may remain suitable for existing holders, while prospective buyers have reason to weigh valuation and execution risk before committing new capital. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Research Chief Names "Single Best Pick to Double"

From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.

This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research